Pfizer's Lipitor share slips, casting doubt on power of a loyalty program to save the brand

Share this article:
Study anticipates higher statin use
Study anticipates higher statin use
Seven weeks after Pfizer's main Lipitor patent expired in the US, the drug is down to 32% market share and at least one name-brand analyst is casting doubt on the brand's survival strategy.

“While this is not the first time that pharma companies have tried (unsuccessfully) to strike post-generic deals with payors, Pfizer's attempts appear to be more aggressive and could set forth a new precedent if successful,” wrote Goldman Sachs analyst Jami Rubin in a Monday analyst note. “However, according to IMS data, Pfizer's share may be starting to slip.”

“Recall,” she added, “that Watson's guidance assumes Pfizer's strategy allows it to retain a 40% market share, and WPI and RBXY split the generic market.”

In fact, Pfizer's share of the market dipped below 40% two weeks after exclusivity loss, languishing at 37% for several weeks before dropping further in recent days.

Pfizer awarded Watson Pharmaceuticals rights on an authorized generic, and that company's CEO, Paul Bisaro, said Pfizer's Lipitor endgame isn't working.

“They're starting to lose market share,” said Bisaro in an analyst meeting, according to Bloomberg. “It appeared they were trying to protect revenue and not profit.”

Watson boasts 27% of the atorvastatin market, according to the IMS numbers, though Bisaro has suggested that IMS undercounts its sales of the drug through Walmart. An unauthorized rival generic by Ranbaxy was in the lead, with 41% share.

Asked about Bisaro's comments, a Pfizer spokesperson said the company's Lipitor For You loyalty program would differentiate the Pfizer product by “increasing patient choice and improving patient adherence by offering Lipitor patients more support than they would receive from a company selling generic atorvastatin,” including a $4 co-pay card, designed to lower patients' out of pocket costs to equal with or lower than the cost of a generic, as well as “counseling, education and adherence tools through expanded partnerships with participating pharmacies.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...